ArticleTheranostics2019
A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications.Clinical and molecular hepatology · 2025Review
- Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate.Molecular pharmaceutics · 2024Article
- Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients.Cancers · 2022Review
- Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma.Journal of gastroenterology and hepatology · 2022Review
- Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.Biosensors & bioelectronics · 2022Article
- Nanoparticles in Clinical Translation for Cancer Therapy.International journal of molecular sciences · 2022Review
- Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis.International journal of molecular sciences · 2021Article
- A comparative study of PCS and PAM50 prostate cancer classification schemes.Prostate cancer and prostatic diseases · 2021Article
- Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma.Advanced materials technologies · 2021Article
- Current status of ctDNA in precision oncology for hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021Review
- Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.American journal of clinical and experimental urology · 2021Article
- Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment.BioMed research international · 2021Review
- A circulating tumor cell-based digital assay for the detection of EGFR T790M mutation in advanced non-small cell lung cancer.Journal of materials chemistry. B · 2020Article
- Cancer transcriptomic profiling from rapidly enriched circulating tumor cells.International journal of cancer · 2020Article
- Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications.Advanced materials (Deerfield Beach, Fla.) · 2020Review
- Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.Theranostics · 2020Article
- ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer.Translational cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Yu Jen JanUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Junhee YoonDivision of Cancer Biology and Therapeutics, Departments of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jie-Fu ChenUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pai-Chi TengUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nu YaoUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Shirley ChengUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Amber LozanoUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Gina C Y ChuUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Howard ChungDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Yi-Tsung LuUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pin-Jung ChenDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Jasmine J WangDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Yi-Te LeeDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Minhyung KimDivision of Cancer Biology and Therapeutics, Departments of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yazhen ZhuDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Beatrice S KnudsenTranslational Oncology Program, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Felix Y FengDepartments of Radiation Oncology, Urology, and Medicine, University of California, San Francisco, San Francisco, California, USA.
Isla P GarrawayDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Allen C GaoDepartment of Urology, University of California Davis, Davis, CA, USA.
Leland W K ChungUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Michael R FreemanDivision of Cancer Biology and Therapeutics, Departments of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sungyong YouDivision of Cancer Biology and Therapeutics, Departments of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Edwin M PosadasUrologic Oncology Program and Uro-Oncology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cedars-Sinai Medical Center · USCalifornia NanoSystems Institute · USUniversity of California, Los Angeles · USUniversity of California, Davis · US
Funding
Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4MA blood test to identify prostate cancer patients at risk for visceral metastasisR01CA218356 · NCI · CEDARS-SINAI MEDICAL CENTER · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2017 to 2021
$3.0MThermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4MCTC Purification System Based on Thermoresponsive NanoSubstratesR44CA180482 · NCI · CYTOLUMINA TECHNOLOGIES CORPORATION, INC · PI LIU, SEAN XIAO, TSENG, HSIAN-RONG · 2015 to 2016
$2.0MMolecular and Functional Analysis of Single Circulating Melanoma CellsR33CA174562 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2015
$987kAdvanced Development of An Integrated CTC Enrichment TechnologyR33CA157396 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2011 to 2013
$672k3D-Nanostrcutured Substrates for Detection of Circulating Tumor CellsR21CA151159 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2010 to 2011
$362kNCI NIH HHS P01 CA098912NCI NIH HHS P01 CA168585NCI NIH HHS R01 CA218356NCI NIH HHS R21 CA151159NCI NIH HHS R33 CA157396NCI NIH HHS R33 CA174562NCI NIH HHS R44 CA180482NCI NIH HHS U01 CA198900
Abstract
PubMed holds no abstract for this paper.
Indexed as
TranscriptomeAndrogen Receptor AntagonistsAntineoplastic AgentsComputational BiologyDrug Screening Assays, AntitumorHumansMaleNeoplastic Cells, CirculatingProstatic Neoplasms, Castration-ResistantRNASignal TransductionAndrogen Receptor AntagonistsAntineoplastic AgentsRNAAndrogen Receptor Signaling InhibitorsCancer RNA ProfilingCirculating Tumor CellMetastatic Castration-Resistant Prostate Cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.